Receptor Protein-Tyrosine Kinases
"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
Descriptor ID |
D020794
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400 D12.776.543.750.630
|
Concept/Terms |
Receptor Protein-Tyrosine Kinases- Receptor Protein-Tyrosine Kinases
- Kinases, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinases, Receptor
- Receptor Protein Tyrosine Kinases
- Receptors, Protein-Tyrosine Kinase
- Protein-Tyrosine Kinase Receptors
- Receptors, Protein Tyrosine Kinase
- PTK Receptors
- Receptors, PTK
- Tyrosine Kinase Receptors
- Protein-Tyrosine Kinase Receptor
- Receptor, Protein-Tyrosine Kinase
- Receptor Protein-Tyrosine Kinase
- Kinase, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinase, Receptor
- Receptor Protein Tyrosine Kinase
- Tyrosine Kinase Linked Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Receptor Protein-Tyrosine Kinases".
- Receptor Protein-Tyrosine Kinases
- c-Mer Tyrosine Kinase
- Discoidin Domain Receptors
- ErbB Receptors
- fms-Like Tyrosine Kinase 3
- Proto-Oncogene Proteins c-kit
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-ret
- Receptor Tyrosine Kinase-like Orphan Receptors
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, IGF Type 1
- Receptor, Insulin
- Receptor, Macrophage Colony-Stimulating Factor
- Receptor, trkA
- Receptor, trkB
- Receptor, trkC
- Receptors, Eph Family
- Receptors, Platelet-Derived Growth Factor
- Receptors, TIE
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 6 | 9 |
1995 | 7 | 2 | 9 |
1996 | 9 | 5 | 14 |
1997 | 6 | 1 | 7 |
1998 | 7 | 3 | 10 |
1999 | 10 | 7 | 17 |
2000 | 6 | 7 | 13 |
2001 | 9 | 8 | 17 |
2002 | 8 | 9 | 17 |
2003 | 11 | 11 | 22 |
2004 | 11 | 11 | 22 |
2005 | 6 | 6 | 12 |
2006 | 5 | 7 | 12 |
2007 | 6 | 8 | 14 |
2008 | 7 | 4 | 11 |
2009 | 5 | 8 | 13 |
2010 | 5 | 5 | 10 |
2011 | 6 | 5 | 11 |
2012 | 6 | 4 | 10 |
2013 | 5 | 4 | 9 |
2014 | 8 | 3 | 11 |
2015 | 11 | 5 | 16 |
2016 | 11 | 3 | 14 |
2017 | 10 | 7 | 17 |
2018 | 7 | 4 | 11 |
2019 | 3 | 2 | 5 |
2020 | 6 | 6 | 12 |
2021 | 7 | 6 | 13 |
2022 | 2 | 14 | 16 |
2023 | 2 | 7 | 9 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer Res Commun. 2024 Mar 14; 4(3):786-795.
-
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis. Endocrinology. 2024 Feb 20; 165(4).
-
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation. Diagn Pathol. 2024 Jan 10; 19(1):10.
-
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2347700.
-
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors. JCO Precis Oncol. 2023 09; 7:e2300217.
-
Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer. Mol Cancer Ther. 2023 07 05; 22(7):818-832.
-
Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. Cancer Commun (Lond). 2023 08; 43(8):951-955.
-
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2023 06 01; 108(6):1604-1615.
-
Extraenteric Malignant Gastrointestinal Neuroectodermal Tumor-A Clinicopathologic and Molecular Genetic Study of 11 Cases. Mod Pathol. 2023 07; 36(7):100160.
-
A Rare PDGFRA Exon 15 Germline Mutation Identified in a Patient With Phenotypic Manifestations Concerning for GIST-Plus Syndrome: A Case Report and Review of Literature. Int J Surg Pathol. 2023 Sep; 31(6):1139-1145.